In This Section      
 

Search Results

Title:
Study of 18F-DCFPyL PET/CT in the Assessment of Patients with Renal Cell Carcinoma
Protocol Number:
J15145
Phase:
NULL
Physician:
Mohamad Allaf
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Johns Hopkins Bayview Medical Center
Purpose:
Pilot study to expand upon the limited existing data on PSMA PET/CT of Renal Cell Carcinoma by imaging a cohort of patients with kidney cancer over a range of disease stages (stage II-IV) and without restriction to the clear cell histologic type. Data may serve to aid in hypothesis generation for the planning of future studies.
Eligibility:
Inclusion1. Age equal to 18 years 2. Clinically diagnosed or histologically proven stage II-IV (T2-4N0M0, TanyN1Many,TanyNanyM1) renal cell carcinoma3. CT or MRI of chest, abdomen and pelvis equal to 45 days prior to study enrollmentExclusion1. History of other malignancy diagnosed within the last 3 years (with the exception of low risk prostate cancer [Gleason score 6, pretreatment PSA equal to 10, cT2a or pT2 if treated], DCIS of the breast, squamous cell carcinoma or basal cell carcinoma of the skin) 2. Administered a radioisotope within 5 physical half-lives prior to study enrollment3. Pregnancy 4. Intention to enroll in a blinded therapeutic clinical trial after PET/CT
Treatment:
Pilot study to expand upon the limited existing data on PSMA PET/CT of Renal Cell Carcinoma by imaging a cohort of patients (N equal to 30)with kidney cancer over a range of disease stages (stage II-IV) and without restriction to the clear cell histologic type. Data may serve to aid in hypothesis generation for the planning of future studies. 18F-DCFPyL administered with scan; participant contacted 3 days after scan.
Population:
Adult
Last Update
03/05/2019 05:03 AM